🔴 Ultragenyx is trading 4.2% down today tracking broader biotech and macro weakness

Ultragenyx is trading at $24.88 (-4.23%) as the stock faces pressure amid a broader biotech risk-off tone and general market weakness.

• No fresh company-specific news, earnings reports, or FDA catalysts have been identified to explain the move.
• The decline appears to be tracking the XBI biotech ETF as markets react to renewed geopolitical and macro pressures.